STOCK TITAN

[SCHEDULE 13G] Inspire Medical Systems, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Citadel and related entities reported ownership stakes in Inspire Medical Systems (INSP). The joint Schedule 13G shows Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC each may be deemed to beneficially own 1,379,861 shares representing 4.7% of outstanding common stock. Citadel Securities LLC reported 114,245 shares (0.4%), and Citadel Securities Group LP and Citadel Securities GP LLC each reported 333,181 shares (1.1%). Mr. Kenneth Griffin is reported with shared beneficial ownership of 1,713,042 shares (5.8%). The filing states holdings are as of the market open on 10/06/2025 and uses a share base of 29,574,316 shares for percentage calculations.

Citadel e le entité correlate hanno riferito partecipazioni azionarie in Inspire Medical Systems (INSP). Il Schedule 13G congiunto mostra che Citadel Advisors LLC, Citadel Advisors Holdings LP e Citadel GP LLC possono essere considerati titolari beneficiari di 1,379,861 azioni rappresentanti 4.7% delle azioni ordinarie in circolazione. Citadel Securities LLC ha riportato 114,245 azioni (0.4%), e Citadel Securities Group LP e Citadel Securities GP LLC ognuna ha riportato 333,181 azioni (1.1%). Il signor Kenneth Griffin viene riportato con proprietà beneficiaria condivisa di 1,713,042 azioni (5.8%). La dichiarazione indica che le partecipazioni sono al mercato aperto il 10/06/2025 e usa come base azionaria 29,574,316 azioni per i calcoli delle percentuali.

Citadel y entidades relacionadas reportaron participaciones en Inspire Medical Systems (INSP). El Schedule 13G conjunto muestra que Citadel Advisors LLC, Citadel Advisors Holdings LP y Citadel GP LLC pueden ser considerados como titulares beneficiarios de 1,379,861 acciones que representan 4.7% de las acciones ordinarias en circulación. Citadel Securities LLC reportó 114,245 acciones (0.4%), y Citadel Securities Group LP y Citadel Securities GP LLC reportaron cada uno 333,181 acciones (1.1%). El señor Kenneth Griffin aparece reportado con propiedad beneficiaria compartida de 1,713,042 acciones (5.8%). El documento indica que las participaciones están al comienzo de la sesión de mercado el 10/06/2025 y usa una base de acciones de 29,574,316 para los cálculos de porcentaje.

Citadel 및 관련 엔티티는 Inspire Medical Systems(INSP)에 대한 지분 보유를 보고했습니다. 공동 Schedule 13G에 따르면 Citadel Advisors LLC, Citadel Advisors Holdings LP 및 Citadel GP LLC는 각각 1,379,861주를 보유한 것으로 간주될 수 있으며 이는 4.7%의 발행 주식에 해당합니다. Citadel Securities LLC는 114,245주를 보고했고 (0.4%), Citadel Securities Group LP와 Citadel Securities GP LLC는 각각 333,181주를 보고했습니다 (1.1%). Kenneth Griffin 씨는 공동 유익 소유로 1,713,042주를 보유한다고 보고되었습니다 (5.8%). 제출서는 보유가 10/06/2025의 시가 개장 시점으로 되어 있으며, 비율 계산의 기초 주식 수를 29,574,316주로 사용한다고 명시합니다.

Citadel et les entités connexe ont signalé des participations dans Inspire Medical Systems (INSP). Le Schedule 13G conjoint indique que Citadel Advisors LLC, Citadel Advisors Holdings LP et Citadel GP LLC peuvent être considérés comme des débiteurs à titre bénéficiaire sur 1 379 861 actions, représentant 4.7% des actions ordinaires en circulation. Citadel Securities LLC a signalé 114 245 actions (0.4%), et Citadel Securities Group LP et Citadel Securities GP LLC chacun a signalé 333 181 actions (1.1%). M. Kenneth Griffin est signalé avec une propriété bénéficiaire partagée de 1 713 042 actions (5.8%). Le dossier indique que les participations sont au début du marché le 10/06/2025 et utilise une base d’actions de 29 574 316 actions pour les calculs des pourcentages.

Citadel und verwandte Einheiten meldeten Eigentumsanteile an Inspire Medical Systems (INSP). Der gemeinsame Schedule-13G zeigt, dass Citadel Advisors LLC, Citadel Advisors Holdings LP und Citadel GP LLC jeweils als wirtschaftlich berechtigt angesehen werden können, 1,379,861 Aktien zu besitzen, was 4,7% der ausstehenden Stammaktien entspricht. Citadel Securities LLC meldete 114,245 Aktien (0.4%), und Citadel Securities Group LP sowie Citadel Securities GP LLC meldeten jeweils 333,181 Aktien (1.1%). Herr Kenneth Griffin wird mit gemeinsamem wirtschaftlichen Eigentum von 1,713,042 Aktien (5.8%) gemeldet. Die Einreichung gibt an, dass die Beteiligungen zum Börsenbeginn am 10/06/2025 bestehen und eine Aktienbasis von 29,574,316 Aktien für die Prozentberechnungen verwendet wird.

قد أبلغت Citadel والكيانات المرتبطة بها عن حصص ملكية في Inspire Medical Systems (INSP). يُظهر Schedule 13G المشترك أن Citadel Advisors LLC وCitadel Advisors Holdings LP وCitadel GP LLC قد يُنظر إليهم كمالكين مستفيدين فعلياً لـ 1,379,861 سهماً، تمثل 4.7% من الأسهم العادية القائمة. وقد أبلغت Citadel Securities LLC عن 114,245 سهماً (0.4%)، وأبلغت Citadel Securities Group LP وCitadel Securities GP LLC عن كل منهما 333,181 سهماً (1.1%). السيد Kenneth Griffin مُسجل بملكية مستفيدة مشتركة قدرها 1,713,042 سهماً (5.8%). وتذكر الإفادة أن الحيازات كما هي عند افتتاح السوق في 10/06/2025 وتستخدم قاعدة أسهم قدرها 29,574,316 سهماً لحساب النسب المئوية.

Citadel及相关实体报告了对 Inspire Medical Systems (INSP) 的所有权股份。 共同的 Schedule 13G 显示 Citadel Advisors LLC、Citadel Advisors Holdings LP 和 Citadel GP LLC 可能被视为对 1,379,861 股的受益所有权,佔未发行普通股的 4.7%。 Citadel Securities LLC 报告了 114,245 股0.4%),Citadel Securities Group LP 与 Citadel Securities GP LLC 各自报告 333,181 股1.1%)。 Kenneth Griffin 先生被报告为具有共同受益所有权的 1,713,042 股5.8%)。 文件指出持股为市场开盘时的情况,日期为 10/06/2025,并以 29,574,316 股作为计算比例的基数。

Positive
  • None.
Negative
  • None.

Insights

Significant passive stake disclosure with clear voting and disposition breakdowns.

The filing reports that several Citadel-affiliated entities together hold meaningful positions in Inspire Medical Systems, with Mr. Kenneth Griffin's aggregated shared beneficial ownership at 5.8%. The statement specifies shared voting and dispositive power rather than sole control, indicating collective influence rather than unilateral control.

The primary dependency is the accuracy of the reported share count and the 29,574,316 share denominator used for percentages. Investors should note the filing characterizes the holdings as not acquired to change or influence control and identifies the reporting date as 10/06/2025. Monitor subsequent filings for changes in position or shifts from shared to sole power within the next reporting window.

Citadel e le entité correlate hanno riferito partecipazioni azionarie in Inspire Medical Systems (INSP). Il Schedule 13G congiunto mostra che Citadel Advisors LLC, Citadel Advisors Holdings LP e Citadel GP LLC possono essere considerati titolari beneficiari di 1,379,861 azioni rappresentanti 4.7% delle azioni ordinarie in circolazione. Citadel Securities LLC ha riportato 114,245 azioni (0.4%), e Citadel Securities Group LP e Citadel Securities GP LLC ognuna ha riportato 333,181 azioni (1.1%). Il signor Kenneth Griffin viene riportato con proprietà beneficiaria condivisa di 1,713,042 azioni (5.8%). La dichiarazione indica che le partecipazioni sono al mercato aperto il 10/06/2025 e usa come base azionaria 29,574,316 azioni per i calcoli delle percentuali.

Citadel y entidades relacionadas reportaron participaciones en Inspire Medical Systems (INSP). El Schedule 13G conjunto muestra que Citadel Advisors LLC, Citadel Advisors Holdings LP y Citadel GP LLC pueden ser considerados como titulares beneficiarios de 1,379,861 acciones que representan 4.7% de las acciones ordinarias en circulación. Citadel Securities LLC reportó 114,245 acciones (0.4%), y Citadel Securities Group LP y Citadel Securities GP LLC reportaron cada uno 333,181 acciones (1.1%). El señor Kenneth Griffin aparece reportado con propiedad beneficiaria compartida de 1,713,042 acciones (5.8%). El documento indica que las participaciones están al comienzo de la sesión de mercado el 10/06/2025 y usa una base de acciones de 29,574,316 para los cálculos de porcentaje.

Citadel 및 관련 엔티티는 Inspire Medical Systems(INSP)에 대한 지분 보유를 보고했습니다. 공동 Schedule 13G에 따르면 Citadel Advisors LLC, Citadel Advisors Holdings LP 및 Citadel GP LLC는 각각 1,379,861주를 보유한 것으로 간주될 수 있으며 이는 4.7%의 발행 주식에 해당합니다. Citadel Securities LLC는 114,245주를 보고했고 (0.4%), Citadel Securities Group LP와 Citadel Securities GP LLC는 각각 333,181주를 보고했습니다 (1.1%). Kenneth Griffin 씨는 공동 유익 소유로 1,713,042주를 보유한다고 보고되었습니다 (5.8%). 제출서는 보유가 10/06/2025의 시가 개장 시점으로 되어 있으며, 비율 계산의 기초 주식 수를 29,574,316주로 사용한다고 명시합니다.

Citadel et les entités connexe ont signalé des participations dans Inspire Medical Systems (INSP). Le Schedule 13G conjoint indique que Citadel Advisors LLC, Citadel Advisors Holdings LP et Citadel GP LLC peuvent être considérés comme des débiteurs à titre bénéficiaire sur 1 379 861 actions, représentant 4.7% des actions ordinaires en circulation. Citadel Securities LLC a signalé 114 245 actions (0.4%), et Citadel Securities Group LP et Citadel Securities GP LLC chacun a signalé 333 181 actions (1.1%). M. Kenneth Griffin est signalé avec une propriété bénéficiaire partagée de 1 713 042 actions (5.8%). Le dossier indique que les participations sont au début du marché le 10/06/2025 et utilise une base d’actions de 29 574 316 actions pour les calculs des pourcentages.

Citadel und verwandte Einheiten meldeten Eigentumsanteile an Inspire Medical Systems (INSP). Der gemeinsame Schedule-13G zeigt, dass Citadel Advisors LLC, Citadel Advisors Holdings LP und Citadel GP LLC jeweils als wirtschaftlich berechtigt angesehen werden können, 1,379,861 Aktien zu besitzen, was 4,7% der ausstehenden Stammaktien entspricht. Citadel Securities LLC meldete 114,245 Aktien (0.4%), und Citadel Securities Group LP sowie Citadel Securities GP LLC meldeten jeweils 333,181 Aktien (1.1%). Herr Kenneth Griffin wird mit gemeinsamem wirtschaftlichen Eigentum von 1,713,042 Aktien (5.8%) gemeldet. Die Einreichung gibt an, dass die Beteiligungen zum Börsenbeginn am 10/06/2025 bestehen und eine Aktienbasis von 29,574,316 Aktien für die Prozentberechnungen verwendet wird.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentages reported in this Schedule 13G are based upon 29,574,316 Shares outstanding as of July 30, 2025 (according to the issuer's Form 10-Q as filed with the Securities and Exchange Commission on August 4, 2025). Except as described in the preceding sentence, all Shares for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on October 6, 2025.


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Citadel Advisors LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:10/06/2025
Citadel Advisors Holdings LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:10/06/2025
Citadel GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:10/06/2025
Citadel Securities LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:10/06/2025
Citadel Securities Group LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:10/06/2025
Citadel Securities GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:10/06/2025
Kenneth Griffin
Signature:/s/ Seth Levy
Name/Title:Seth Levy, attorney-in-fact*
Date:10/06/2025

Comments accompanying signature: * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.
Exhibit Information

Exhibit 99.1 - Joint Filing Agreement

Inspire Medical

NYSE:INSP

INSP Rankings

INSP Latest News

INSP Latest SEC Filings

INSP Stock Data

2.26B
26.85M
1.14%
117.62%
7.94%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
GOLDEN VALLEY